OpenAI收购Orchestra Bio，助力生命科学研发AI化
openai 收购 orchestra bio，以 ai 助力生命科学研发，加速药物开发。
openai is acquiring orchestra bio to integrate ai-powered operations into life sciences research and development. this move aims to help biopharma teams accelerate drug development processes and advance new treatments. by leveraging ai, openai seeks to enhance the efficiency of r&d in the life sciences sector. the acquisition is expected to impact the biopharma industry. openai's strategy involves applying ai to improve drug development.